Clinical trials: Adjuvant Treatment
Cutaneous Squamous Cell Carcinoma (CSCC)
MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer
The goal of this clinical trial is to evaluate if short-course radiation therapy (SCRT) can effectively treat high-risk cutaneous squamous cell carcinoma (cSCC) and if active surveillance is a safe alternative to radiation for…
- Trial name
- MOHSAHRTSS (NCT06998342)
- Testing
- Short course radiation, Active Surveillance
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Renal Cell Carcinoma
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following…
- Trial name
- IMmotion010 (NCT03024996)
- Testing
- Atezolizumab
- Where
- 186 sites in United States, Argentina and 26 more
- Volunteers
- 778 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients…
- Trial name
- @FAME (NCT00357110)
- Testing
- Fulvestrant, Anastrozole
- Where
- 25 sites in Austria, Germany and 1 more
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Ketamine Causing Adverse Effects in Therapeutic Use
Comparing Three Different Doses of Intrathecal Ketamine
The aim of this study is to compare the postoperative analgesic effect of three different doses of intrathecal ketamine as an adjuvant to bupivacaine in patients undergoing knee arthroscopy.
- Trial name
- NCT05074823
- Testing
- Ketamine 0.1 mg, Ketamine 0.2 mg, Ketamine 0.3 mg
- Where
- Egypt
- Volunteers
- 105 people
- Sponsor
- Assiut University
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer
This trial will compare grade 2 or greater late skin toxicities of concomitant letrozole-radiotherapy and radiotherapy followed by letrozole as adjuvant therapy for postmenopausal women with receptor (estrogen receptor [ER]…
- Trial name
- NCT00208273
- Testing
- Letrozole - Concomitant, Letrozole - Sequential
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old…
- Trial name
- NCT01712893
- Testing
- Zoladex
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Fudan University
Uterine Sarcoma
The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas
This is a Phase III study about the effects of the addition of polychemotherapy to adjuvant radiotherapy in the treatment of non-metastatic uterine sarcomas.
- Trial name
- NCT00162721
- Testing
- doxorubicin, ifosfamide, cisplatin
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.
The goal of this clinical trial is to learn whether letrozole, a hormone therapy drug, is effective in treating early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to nearby lymph nodes in…
- Trial name
- NELOPHER (NCT07394946)
- Testing
- Letrozole
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Cancer Care Hospital & Research Centre Foundation, Lahore
Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients
To evaluate the safety and tolerability of satri-cel as consolidation therapy after postoperative adjuvant therapy in patients with resected gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
- Trial name
- CT041-CG4010 (NCT06857786)
- Testing
- Drug: CT041 autologous CAR T-cell injection
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Peking University
Lung Cancer
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC.
- Trial name
- NCT00193427
- Testing
- Docetaxel, Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- SCRI Development Innovations, LLC
TNBC, Adjuvant Therapy
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
This study is a prospective, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of postoperative chemotherapy combined with QL1706 in patients with high-risk triple-negative breast cancer.
- Conditions
- TNBC, Adjuvant Therapy, Lymph Node Positive
- Trial name
- NCT07622836
- Testing
- Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Stage II Breast Cancer, Stage IIIA Breast Cancer
Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen and progesterone can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen and progesterone.
- Conditions
- Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00080613
- Testing
- exemestane, adjuvant therapy, aromatase inhibition
- Where
- United States
- Sponsor
- Robert H. Lurie Cancer Center
Type 2 Diabetes Mellitus, Obesity
RCT Examining Effects of Probiotics in T2DM Individuals
Background: The connection between gut health and diabetes status is increasingly recognized. Gut microbiota composition in diabetic differs from non-diabetic individuals.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Hypertension, Hyperlipidemia
- Trial name
- NCT01752803
- Testing
- Probiotic
- Where
- Malaysia
- Volunteers
- 100 people
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
Prostate Cancer, Prostatic Adenocarcinoma
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has…
- Trial name
- NCT01542021
- Testing
- degarelix injection, androgen deprivation therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Cancer
Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment.
In the REaCT-Vascular Access Trastuzumab study (REaCT-VA), the investigator will use a novel method to allow comparisons of established standard of care vascular access strategies using the "integrated consent model" as part of a…
- Trial name
- OTT 15-06 (NCT02632435)
- Testing
- PICC, PORT
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Ottawa Hospital Research Institute
Adult Glioblastoma, Adult Gliosarcoma
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase II trial studies temozolomide, radiation therapy, and cediranib maleate to see how well they work compared with temozolomide, radiation therapy, and a placebo in treating patients with newly diagnosed…
- Trial name
- NCT01062425
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cediranib Maleate, Intensity-Modulated Radiation Therapy
- Where
- 105 sites in United States
- Volunteers
- 261 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Total Neoadjuvant Treatment of Rectal Cancer by MRI-guided Radiotherapy
The TNTRect trial is a prospective observational study that will evaluate the outcome of MR-guided stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost in a hypofractionated treatment of rectum cancer.
- Trial name
- TNTRect (NCT05916040)
- Testing
- Radiotherapy with MRIdian with simultaneous integrated boost, Questionnaires before, during and after radiotherapy
- Where
- Belgium
- Volunteers
- 35 people
- Sponsor
- Universitair Ziekenhuis Brussel
Prostate Cancer
Genomics in Michigan Impacting Observation or Radiation
To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.
- Trial name
- G-MINOR (NCT02783950)
- Testing
- Decipher Prostate Cancer Classifier
- Where
- 13 sites in United States
- Volunteers
- 356 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue and may improve quality of life and help patients live more…
- Trial name
- NCT00067015
- Testing
- bicalutamide, goserelin acetate, assessment of therapy complications
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.